Publications & Presentations
Rademikibart - Respiratory
Rademikibart - Dermatology
Rademikibart monotherapy for moderate-to-severe atopic dermatitis in a 1-year, randomized, phase II trial (SEASIDE CHINA): initial two-week dosing, followed by two-week or four-week dosing
Zhang J, Silverberg J, Guo J, Yun J, Pan W, Wei Z, Collazo R . Br J Dermatol. Published online September 2, 2025. doi:10.1093/bjd/ljaf347
Rademikibart (CBP-201), a next-generation monoclonal antibody targeting human IL-4Rα: Two phase I randomized trials, in healthy individuals and patients with atopic dermatitis.
Wang J, White J, Sansone KJ, Spelman L, Sinclair R, Yang X, Pan W, Wei Z. Clin Transl Sci. 2023 Dec;16(12):2614-2627. doi: 10.1111/cts.13656.
A Mini Review of the Impact of Baseline Disease Severity on Clinical Outcomes: Should We Compare Atopic Dermatitis Clinical Trials?
Silverberg JI, Ho S, Collazo R. Dermatol Ther (Heidelb). 2023 Dec;13(12):3019-3029. doi: 10.1007/s13555-023-01052-5.
Efficacy and safety of rademikibart (CBP-201), a next-generation mAb targeting IL-4Rα, in adults with moderate to severe atopic dermatitis: A phase 2 randomized trial (CBP-201-WW001).
Silverberg JI, Strober B, Feinstein B, Xu J, Guttman-Yassky E, Simpson EL, Li P, Longphre M, Song J, Guo J, Yun J, Williams B, Pan W, Ho S, Collazo R, Wei Z. J Allergy Clin Immunol. 2024 Apr;153(4):1040-1049.e12. doi: 10.1016/j.jaci.2023.11.924.
Rademikibart - Discovery
Biologic Therapies Targeting Type 2 Signaling in Atopic Dermatitis: A Comparative Review of Structural and Thermodynamic Differences in Mechanism of Action
Bunick C. J Invest Dermatol. Published online August 6, 2025. doi:10.1016/j.jid.2025.06.1574.
Preclinical immunological characterization of rademikibart (CBP-201), a next-generation human monoclonal antibody targeting IL-4Rα, for the treatment of Th2 inflammatory diseases.
Zhang L, Ding Y, Wang Q, Pan W, Wei Z, Smith PA, Yang X. Sci Rep. 2023 Jul 31;13(1):12411. doi: 10.1038/s41598-023-39311-2.
Icanbelimod – Ulcerative Colitis (UC)
Clinical
Icanbelimod (CBP-307), a next-generation Sphingosine-1-phosphate receptor modulator, in healthy men: pharmacokinetics, pharmacodynamics, safety, and tolerability in a randomized trial in Australia.
Lickliter J, Yang X, Guo J, Pan W, Wei Z. Front Immunol. 2024 Jun 17;15:1380975. doi: 10.3389/fimmu.2024.1380975.
Discovery
Structural insights into sphingosine-1-phosphate receptor activation.
Yu L, He L, Gan B, Ti R, Xiao Q, Hu H, Zhu L, Wang S, Ren R. Proc Natl Acad Sci U S A. 2022 Apr 19;119(16):e2117716119. doi: 10.1073/pnas.2117716119. Erratum in: Proc Natl Acad Sci U S A. 2022 Aug 23;119(34):e2209949119. doi: 10.1073/pnas.2209949119.